P-cadherin-mediated adherens junctions and the associated signaling pathway play diverse roles in the regulation of tumor cell proliferation, invasiveness and metastatic potential. Upregulation of P-cadherin was frequently observed in various malignancies, including breast, colon, lung and pancreatic tumors, and P-cadherin increase correlated with poor survival of breast cancer patients. PF-03732010, a novel, highly selective human monoclonal antibody against P-cadherin, demonstrated antitumor and antimetastatic activity in a diverse panel of P-cadherin-overexpressing tumor models without introducing any adverse effects. Mechanistic studies revealed that PF-03732010 disrupted the P-cadherin signaling pathway, suppressed β-catenin transcriptional targets, and resulted in antimetastatic, antiproliferative activity and the induction of apoptosis.
Introduction
The classic cadherins constitute a superfamily of molecules that mediate calciumdependent cell-cell adhesions. The intracellular domains of cadherins directly bind to β-catenin and link with cytoskeletal components, providing the molecular basis for stable cell-cell adhesion (1) . The cadherin/catenin signaling pathway also represents a major regulatory mechanism for oncogenic signaling pathways (2) (3) that guide cell fate Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research manufacturer's protocols. 4T1-CDH3 cells were transfected to express high levels of Pcadherin. Target cell lines were transduced with retroviral vectors, and drug-resistant pools of cells were selected with Geneticin at 0.5 mg/ml. DU145, H1650 and HCT116, along with the MDA-MB-435HAL and PC3M isogenic pairs, stably expressed luciferase to allow disease progression to be monitored by BLI imaging.
Cell aggregation and spheroid disruption assays
To perform the aggregation assay, cells were detached and resuspended as single cells at a concentration of 1 x 10 6 cells/ml. Cells were plated into 96-well Poly-Hema-coated plates and incubated with and without the test agent(s) at 37°C on a horizontal shaker for 16 hr to facilitate aggregate formation. For the spheroid disruption experiments, cell aggregates were formed prior to being treated, and activity was expressed as fold increase in disrupted cells compared to untreated controls.
Cells or aggregates were fixed with 4% formaldehyde, and the degree of aggregation was scanned and calculated using a Cellomics® ArrayScan® (Thermo Fisher Scientific) equipped with Target Acquisition software. Maximal inhibition was defined as the value when EGTA was present, during which the maximum number of single non-aggregated cells was produced, whereas the negative control was the value when the smallest number of cell-cell aggregates was formed in complete medium. EC50 values were determined using Graphpad Prism software.
In vivo studies and drug administration
All animal experimental procedures complied with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 1996) and were approved Figure 1) . The once-weekly subcutaneous dosing schedule was also employed in the subsequent in vivo experiments for efficacy and pharmacodynamic endpoint evaluations. For the efficacy assessments, mice (Charles River) were randomly assigned to groups (12 mice per group) prior to treatment, such that the mean tumor size was equal for all groups. In studies assessing efficacy, PF-03732010 was administered subcutaneously once per week for 6 to 9 weeks.
For all studies in this report, no adverse effects were observed in mice treated with PF-03732010.
Tumor models
SCID-beige mice were used for all studies in this report, except when using 4T1-CDH3 cells, for which normal BALB/c mice were used. For the mammary orthotopic implant, 2 X 10 6 cells were combined with matrigel and injected into the mice under the mammary fat-pad. Details for the prostate orthotopic and subrenal capsule tumor (SRC) models were described previously (27, 28) . For the H1650 orthotopic or lung metastasis models, 2 X 10 6 cells were intravenously injected through the tail vein of anesthetized mice.
Tumors in the lungs were identified via bioluminescence within two weeks after tumor 
Bioluminescence imaging
In vivo bioluminescence imaging (BLI) was conducted using the IVIS100 
qPCR and Western blot analysis
The circulating tumor cells (CTCs) in mouse whole blood were evaluated by real time quantitative PCR (RT-PCR) analysis of human Alu DNA-sequences, which has been previously validated by laser scanning cytometry (29) . Western blot analysis was performed according to the antibody manufacturer's instructions. Tumors were snapfrozen and pulverized in a liquid nitrogen-cooled mortar prior to analysis. respectively, as described previously (30) . The standardized uptake value (SUV) was calculated using the following formula:
Immunofluorescence and immunohistochemical staining
where C PET is the measured activity in the volume of interest, ID is the injected dose (µCi) and W is the mouse body weight.
Data analysis
Tumor growth inhibition (TGI) was calculated as 100*(1-ΔT/ΔC). The ΔC (ΔT) was obtained by subtracting the mean tumor volume in the vehicle (treated) group on the first day of treatment from the mean tumor volume at the day of assessment. Statistical analyses were conducted using GraphPad Prism with one-way ANOVA analysis, followed by Dunnet's t-test to compare the tumor sizes between the vehicle-and drugtreated groups.
Results
Affinity and specificity of PF-03732010 against P-cadherin respectively, suggesting similar affinities toward both proteins. Because the extracellular domain of human and mouse mature P-cadherin proteins share 87% homology (31), PF-03732010 demonstrated comparable cross-reactivity with human and mouse P-cadherins.
The selectivity of PF-03732010 was tested on immobilized P-cadherin versus other related cadherins via an ELISA format (Supplement Figure 2) , and PF-03732010 did not exhibit significant binding to E-cadherin, N-cadherin, or VE-cadherin recombinant proteins across a broad range of concentrations.
To confirm that PF-03732010 does not bind to E-cadherin, cell-based flow cytometric analysis was performed using A549 cells, which exhibit high E-cadherin expression but no detectable P-cadherin expression. Figure 1A shows that binding of PF-03732010 to A549 cells was not detected.
In vitro functional assay of PF-03732010
P-cadherin expression in the cell lines used in this report was tested by immunoblot analysis (Supplement Figure 3 ). High levels of P-cadherin were observed in HCT116, DU145 and H1650, as well as the cell lines engineered to express P-cadherin (CDH3). In contrast, vector-transfected (pCL) lines showed minimal expression of P-cadherin. model. These data demonstrate that the disruption of the P-cadherin/β-catenin signaling pathway corresponds with diminished tumor cell invasiveness, proliferation and increased apoptosis. E-cadherin levels were below the level of detection in this model therefore we were unable to determine whether E-cadherin plays a role in this signaling cascade.
In the PC3M-CDH3 prostate orthotopic model ( Figure 5D PF-03732010 demonstrated high specificity and selectivity for P-cadherin targeting. The
IgG failed to bind to the most closely target-related family members, including E-, N-and VE-cadherin, as assessed by ELISA using recombinant proteins. In the PC3M-pCL and the MDA-MB-435HAL-pCL models, which express high level of N-cadherin but lack Pcadherin, treatment with PF-03732010 showed no therapeutic benefit. These data suggest that the IgG-associated efficacy was not due to the off-target activity by antagonizing N-cadherin. Specifically, PF-03732010 also lacked the ability to bind to endogenous E-cadherin in cell-based FACS analyses, confirming the high selectivity of the antibody to P-cadherin over E-cadherin. Because E-cadherin shares some homology with P-cadherin, and E-cadherin functionally suppresses tumorigenesis or metastasis (32) , the high specificity of PF-03732010 for P-cadherin over E-cadherin would allow a better therapeutic window to be achieved.
PF-03732010 impairs P-cadherin-mediated cell function, and at nanomolar concentrations, the antibody also blocked P-cadherin-mediated cell-cell adhesion and disrupted pre-established spheroids.
In tumor models, PF-03732010 induced significant tumor growth inhibition, although this antiproliferative activity was not observed when cells were treated with PF-03732010 in vitro. This discrepancy suggests that fully functioning P-cadherin signaling may require the cell-cell and cell-stroma cross talk in an intact tumor architecture during tumorigenesis and metastasis, a process that may not be recapitulated under in vitro conditions. In the experimental system, we used P-cadherin-deficient MDA-MB-231, 
